We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

206 hedge funds and large institutions have $429M invested in Inovio Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 60 increasing their positions, 63 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more capital inflows, than outflows

Capital inflows: $71.5M | Capital outflows: $18.3M

4.02% more ownership

Funds ownership: 36.84% → 40.86% (+4%)

5% less repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 63

3% less funds holding

Funds holding: 213 → 206 (-7)

15% less call options, than puts

Call options by funds: $15.5M | Put options by funds: $18.2M

49% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 39

Holders
206
Holders Change
-7
Holders Change %
-3.29%
% of All Funds
3.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
60
Reduced
63
Closed
39
Calls
$15.5​M
Puts
$18.2​M
Net Calls
-⁠$2.67​M
Net Calls Change
+$4.22​M

INO Hedge Fund Activity: Q4 2021 in Review

206 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2021, worth a combined $429M — down 23% from $555M a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of INO and 20 opened new positions — a net loss of 19 holders — while 63 trimmed existing stakes and 60 added.

The largest buyer was State Street, adding an estimated $15.7M. The largest seller was JP Morgan Chase, cutting an estimated $2.07M.

  • 206 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2021, down from 213 in Q3 2021.
  • Funds reported $429M of Inovio Pharmaceuticals stock for Q4 2021, down 23% quarter-over-quarter.
  • 20 funds opened new Inovio Pharmaceuticals positions in Q4 2021 and 39 closed out, a net change of -19 holders.
  • The largest Inovio Pharmaceuticals buyer in Q4 2021 was State Street, an estimated $15.7M added.
  • The largest Inovio Pharmaceuticals seller in Q4 2021 was JP Morgan Chase, an estimated $2.07M sold.

Based on aggregated 13F filings for Q4 2021.